June 30, 2020 / 4:46 PM / 8 days ago

BRIEF-NOXXON Enrolls First Patient In Second Dose Cohort Of Trial Combining NOX-A12 With Radiotherapy In Newly Diagnosed Brain Cancer

June 30 (Reuters) - NOXXON Pharma NV:

* NOXXON ENROLLS FIRST PATIENT IN SECOND DOSE COHORT OF TRIAL COMBINING NOX-A12 WITH RADIOTHERAPY IN NEWLY DIAGNOSED BRAIN CANCER

* STUDY INVESTIGATES THREE DOSE REGIMENS OF NOX-A12 (200, 400 AND 600 MG/WEEK), EACH COMBINED WITH EXTERNAL-BEAM RADIOTHERAPY IN NEWLY DIAGNOSED BRAIN CANCER PATIENTS

* SIX MONTHS OF DATA FROM FIRST COHORT OF PATIENTS SHOULD BE AVAILABLE IN OCTOBER 2020, AND FROM SECOND AND THIRD COHORTS AT END OF Q1 2021 AND MID-2021, RESPECTIVELY Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below